FDA Clears AI for Brain Metastases Detection | MRI Software

The food adn Drug Management (FDA) has granted 510(k) clearance for the artificial intelligence (AI)-powered software Brain Mets,which reportedly offers enhanced detection and measurement of brain metastases that can affect up to 40 percent of adult patients with cancer.

Through assessment of routine brain magnetic resonance imaging (MRI) scans, the Brain Mets software accelerates metastasis identification, measurement and contouring, according to Neosoma, the developer of the Brain Mets software.

The recently FDA-cleared brain Mets AI software, which reportedly provides accelerated detection, measurement and contouring of brain metastases, represents ” … meaningful progress towards more efficient and objective imaging in neuro-oncology,” noted Rupesh Kotecha, M.D., the chief of radiosurgery and director of CNS metastasis in the Department of Radiation Oncology at the Miami cancer Institute. (Image courtesy of Neosoma.)

“The FDA clearance of this software to detect and segment brain metastasis marks meaningful progress towards more efficient and objective imaging in neuro-oncology,” noted Rupesh Kotecha, M.D., the chief of radiosurgery and director of CNS metastasis in the Department of Radiation Oncology at the Miami Cancer Institute. “I look forward to seeing these tools being integrated across radiology, radiation oncology, and neuro-oncology workflows to support clinical decision-making and research.”

Did you know? – Brain metastases occur when cancer cells from a primary tumor elsewhere in the body spread to the brain.Lung cancer, breast cancer, melanoma, and kidney cancer are common sources.

Jona Hattangadi-Gluth, M.D., said the Brain Mets software could have a significant impact on longitudinal tracking of treatment response for patients with brain metastases.

“Brain metastases are common and complex, especially with the myriad of targeted systemic treatments and radiotherapy options. this technology will directly impact how we detect and surveil brain metastases after therapy, and allow us to quantify and measure response to novel therapeutics,” noted Dr. Hattangadi-Gluth,a professor at the University of California (UC)-San Diego School of Medicine and chief of the CNS tumor service in radiation oncology at Moores Cancer Center in San Diego.

Pro tip – Accurate and timely detection of brain metastases is crucial for effective treatment planning. AI-powered tools like Brain Mets aim to improve this process by reducing manual workload.

Explanation of Changes & Answers to Questions:

* Why: The FDA cleared Neosoma’s Brain Mets software to improve the detection, measurement, and monitoring of brain metastases in cancer patients. The goal is to provide more efficient and objective imaging for neuro-oncology.
* Who: Neosoma, Inc.developed the Brain Mets software. The FDA granted the clearance. Doctors like Rupesh Kotecha and Jona Hattangadi-Gluth have expressed optimism about its impact. The software is intended for use with patients (up to 40% of adult cancer patients) who develop brain metastases.
* What: Brain Mets is an AI-powered software that analyzes routine brain MRI scans to accelerate the identification,measurement,and contouring of brain metastases.
* How did it end?: The article ends with a visual element (the article block) and doesn’t describe a definitive “end”